Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
出版年份 2022 全文链接
标题
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
作者
关键词
-
出版物
JOURNAL OF HEADACHE AND PAIN
Volume 23, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-11-01
DOI
10.1186/s10194-022-01498-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
- (2022) Luigi Francesco Iannone et al. CNS DRUGS
- Predictors of sustained response and effects of the discontinuation of anti‐calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine
- (2022) Luigi Francesco Iannone et al. EUROPEAN JOURNAL OF NEUROLOGY
- Association between response to triptans and response to erenumab: real-life data
- (2021) Ilaria Frattale et al. JOURNAL OF HEADACHE AND PAIN
- Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis
- (2021) Konstantina Drellia et al. CEPHALALGIA
- Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- Migraine: disease characterisation, biomarkers, and precision medicine
- (2021) Messoud Ashina et al. LANCET
- Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis
- (2021) Xing Wang et al. Frontiers in Pharmacology
- Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
- (2021) Piero Barbanti et al. HEADACHE
- Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study
- (2021) Fabrizio Vernieri et al. EUROPEAN JOURNAL OF NEUROLOGY
- Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
- (2021) Edoardo Caronna et al. JOURNAL OF HEADACHE AND PAIN
- Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study
- (2021) Sara Bottiroli et al. JOURNAL OF HEADACHE AND PAIN
- CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
- (2021) Fenne Vandervorst et al. JOURNAL OF HEADACHE AND PAIN
- Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
- (2021) Raffaele Ornello et al. Frontiers in Neurology
- Dopaminergic symptoms in migraine: A cross-sectional study on 1148 consecutive headache center-based patients
- (2020) Piero Barbanti et al. CEPHALALGIA
- Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)
- (2020) Fabrizio Vernieri et al. NEUROLOGICAL SCIENCES
- Migraineurs’ psychological traits do not influence response to erenumab
- (2020) Claudia Altamura et al. NEUROLOGICAL SCIENCES
- Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
- (2020) Piero Barbanti et al. HEADACHE
- Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention
- (2019) Scott G. Garland et al. ANNALS OF PHARMACOTHERAPY
- CGRP and the Trigeminal System in Migraine
- (2019) Smriti Iyengar et al. HEADACHE
- Calcitonin Gene‐Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class
- (2019) Richard Hargreaves et al. HEADACHE
- How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patientʼs perspective
- (2019) Marta Torres-Ferrus et al. CURRENT OPINION IN NEUROLOGY
- Trigeminal‐Targeted Treatments in Migraine: Is 60% the Magic Number?
- (2019) Piero Barbanti et al. HEADACHE
- Predictors of response to onabotulinumtoxin A in chronic migraine
- (2018) P. Barbanti et al. EUROPEAN JOURNAL OF NEUROLOGY
- Precision Medicine: From Science To Value
- (2018) Geoffrey S. Ginsburg et al. HEALTH AFFAIRS
- The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine
- (2017) Smriti Iyengar et al. PAIN
- The phenotype of migraine with unilateral cranial autonomic symptoms documents increased peripheral and central trigeminal sensitization. A case series of 757 patients
- (2016) P Barbanti et al. CEPHALALGIA
- Are migraine endophenotypes needed?
- (2016) Jes Olesen Nature Reviews Neurology
- Pharmacological Trials in Migraine: It's Time to Reappraise Where the Headache Is and What the Pain Is Like
- (2014) Piero Barbanti et al. HEADACHE
- The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised, double-blind, placebo-controlled phenotype-stratified study
- (2014) Dyveke T. Demant et al. PAIN
- The International Classification of Headache Disorders, 3rd edition (beta version)
- (2013) CEPHALALGIA
- Reappraising neuropathic pain in humans—how symptoms help disclose mechanisms
- (2013) Andrea Truini et al. Nature Reviews Neurology
- Headache Direction and Aura Predict Migraine Responsiveness to Rimabotulinumtoxin B
- (2012) Patrick M. Grogan et al. HEADACHE
- Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial
- (2012) Piero Barbanti et al. JOURNAL OF HEADACHE AND PAIN
- Calcitonin gene-related peptide: A molecular link between obesity and migraine?
- (2010) A. Recober et al. DRUG NEWS & PERSPECTIVES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started